Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease.

Step therapy processes and rules can vary in terms of how many steps are required. Sometimes a person is required to “fail first” with only one lower-cost medication, while other coverage decisions require a person to “fail first” trying multiple medications.

Throughout the course of Parkinson’s disease, levodopa therapy becomes increasingly complicated by the development of OFF episodes and the emergence of dyskinesia.

When treated with amantadine extended-release capsules (GOCOVRI), patients with Parkinson disease saw improvements in both dyskinesia and motor aspects of experiences of daily living (M-EDLs), namely tremor, freezing, eating, and getting in and out of the seated position, according to findings from 2 randomized phase 3 trials published in ‘Neurology Therapy’.

An executive profile from the San Francisco Business Times.

Those beginning standard treatment for Parkinson’s tend to experience OFF episodes or dyskinesias. Dr. Adrian Quartel at Adamas Pharmaceuticals explores how those with the disease can have improved quality of life and better wellbeing by treating its myriad complications.

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.

Adamas Pharmaceuticals, Inc.’s Gocovri (amantadine extended release) received U.S. Food and Drug Administration (FDA) approval for a new indication — Parkinson’s “off” time, when symptoms return between medication doses. The drug was previously approved, in 2017, for dyskinesia – involuntary movement that can develop with many years of Parkinson’s and taking levodopa.

Gocovri (amantadine) has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for off episodes in people with Parkinson’s disease. Adamas Pharmaceuticals, which developed the therapy, announced its approval in the U.S. for Parkinson’s patients currently taking levodopa and/or carbidopa.